| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 39, 312-316, Copyright © 1993 by American Association for Clinical Chemistry
JE Buttery and S Stuart
Department of Clinical Chemistry, Queen Elizabeth Hospital, Woodville, South Australia.
In the kinetic angiotensin-converting enzyme (ACE) method, a practical and optimal buffer is 80 mmol/L borate buffer at pH 8.2 (37 degrees C). A lag phase is detected in the reaction, and a 5-min incubation of substrate and plasma is suggested before the kinetic measurement. The substrate, N-[3-(2-furyl)acryloyl]-L-phenylalanylglycylglycine (FAPGG), concentration is maximized at 1.0 mmol/L and the measurement wavelength is at 345 nm to ensure linearity of measurement. The proposed procedure uses a 1:9 plasma-to-reagent volume ratio. The linear range of the assay extends to approximately 170 U/L, representing a 25% substrate hydrolysis. The FAPGG absorptivity is determined by measuring the difference in absorbance between 1.0 mmol/L FAPGG and the product solutions. The wavelength fidelity is checked by noting the expected absorbance value of the FAPGG solution, and a 1.0-nm deviation from 345 nm alters the absorbance by 15.5%. The precision of ACE assays at approximately 60 and 100 U/L is 3.5% and 2.4% within batch and 2.9% and 2.6% between batch, respectively. The reference interval (2.5th to 97.5th percentiles) is 41-139 U/L, and there is no difference between values for men and women.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  T. E. Scholzen, S. Konig, M. Fastrich, M. Bohm, and T. A. Luger Terminating the Stress: Peripheral Peptidolysis of Proopiomelanocortin-Derived Regulatory Hormones by the Dermal Microvascular Endothelial Cell Extracellular Peptidases Neprilysin and Angiotensin-Converting Enzyme Endocrinology, June 1, 2007; 148(6): 2793 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nordfeldt and U. Samuelsson Serum ACE Predicts Severe Hypoglycemia in Children and Adolescents With Type 1 Diabetes Diabetes Care, February 1, 2003; 26(2): 274 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schiavello, V. Burke, N. Bogdanova, P. Jasik, S. Melsom, N. Boudville, K. Robertson, D. Angelicheva, B. Dworniczak, M. Lemmens, et al. Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2323 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. van Ittersum, A. M. E. de Man, S. Thijssen, P. de Knijff, E. Slagboom, Y. Smulders, L. Tarnow, A. J. M. Donker, H. J. G. Bilo, and C. D. A. Stehouwer Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus Nephrol. Dial. Transplant., July 1, 2000; 15(7): 1000 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.J. Emeis, Y. v. d. Eijnden-Schrauwen, C.M. v. d. Hoogen, W. d. Priester, A. Westmuckett, and F. Lupu An Endothelial Storage Granule for Tissue-Type Plasminogen Activator J. Cell Biol., October 6, 1997; 139(1): 245 - 256. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
